See more : Mechema Chemicals International Corp. (4721.TWO) Income Statement Analysis – Financial Results
Complete financial analysis of Polarean Imaging plc (PLLWF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Polarean Imaging plc, a leading company in the Medical – Devices industry within the Healthcare sector.
You may be interested
- Fidelity China Special Situations PLC (FECHF) Income Statement Analysis – Financial Results
- State Grid Information & Communication Co., Ltd. (600131.SS) Income Statement Analysis – Financial Results
- Country Garden Holdings Company Limited (CTRYY) Income Statement Analysis – Financial Results
- China Customer Relations Centers, Inc. (CCRC) Income Statement Analysis – Financial Results
- Shanghai Huace Navigation Technology Ltd (300627.SZ) Income Statement Analysis – Financial Results
Polarean Imaging plc (PLLWF)
About Polarean Imaging plc
Polarean Imaging plc operates as a medical drug-device combination company serving the medical imaging market in the United States, Canada, Germany, and the United Kingdom. The company engages in the development and commercialization of gas polarizer devices and ancillary instruments. It develops equipment that enables existing magnetic resonance imaging (MRI) systems to achieve a level of pulmonary functional imaging and specializes in the use of hyperpolarized xenon gas (129Xe) as an imaging agent to visualize ventilation and gas exchange regionally in the smallest airways of the lungs, the tissue barrier between the lung and the bloodstream, and in the pulmonary vasculature; and a novel diagnostic approach. The company is also involved in the development and manufacture of MRI radiofrequency coils, which are required components for imaging 129Xe in the MRI system. Polarean Imaging plc was incorporated in 2016 and is based in Durham, North Carolina.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 890.93K | 1.03M | 1.19M | 1.06M | 2.30M | 2.44M | 1.24M | 880.65K | 902.34K | 965.43K |
| Cost of Revenue | 555.45K | 684.73K | 677.40K | 346.30K | 925.61K | 633.46K | 297.22K | 488.89K | 308.56K | 168.03K |
| Gross Profit | 335.48K | 348.28K | 508.03K | 710.47K | 1.38M | 1.81M | 939.95K | 391.76K | 593.78K | 797.40K |
| Gross Profit Ratio | 37.66% | 33.71% | 42.86% | 67.23% | 59.78% | 74.03% | 75.98% | 44.49% | 65.80% | 82.60% |
| Research & Development | 4.19M | 607.76K | 638.59K | 480.89K | 161.31K | 642.46K | 176.11K | 145.44K | 162.98K | 269.83K |
| General & Administrative | 3.34M | 8.46M | 6.52M | 5.05M | 6.01M | 6.16M | 4.05M | 1.28M | 1.19M | 769.96K |
| Selling & Marketing | 3.56M | 3.31M | 5.56M | 917.78K | 324.79K | 31.77K | 28.75K | 35.24K | 25.39K | 86.41K |
| SG&A | 6.90M | 11.78M | 12.08M | 5.97M | 6.33M | 6.19M | 4.08M | 1.32M | 1.21M | 856.37K |
| Other Expenses | 1.80M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 12.89M | 14.02M | 14.82M | 7.33M | 7.39M | 7.07M | 4.86M | 1.45M | 1.51M | 869.11K |
| Cost & Expenses | 13.45M | 14.70M | 15.50M | 7.67M | 8.31M | 7.71M | 5.16M | 1.94M | 1.81M | 1.04M |
| Interest Income | 759.00 | 35.05K | 2.59K | 100.77K | 508.00 | 184.00 | 129.00 | 147.00 | 159.31K | 37.69K |
| Interest Expense | 15.99K | 23.76K | 20.74K | 19.73K | 91.68K | 188.06K | 34.06K | 4.32K | 0.00 | 0.00 |
| Depreciation & Amortization | 959.78K | 1.02M | 918.40K | 942.62K | 775.69K | 598.87K | 387.84K | 9.35K | 9.99K | 12.74K |
| EBITDA | -11.19M | -12.78M | -13.38M | -5.73M | -5.26M | -4.64M | -3.55M | -1.05M | -617.40K | -58.97K |
| EBITDA Ratio | -1,256.55% | -1,243.32% | -1,128.88% | -532.81% | -228.79% | -190.22% | -287.32% | -118.80% | -68.42% | -6.11% |
| Operating Income | -12.56M | -13.67M | -14.32M | -6.62M | -6.01M | -5.27M | -3.92M | -1.06M | -627.39K | -71.71K |
| Operating Income Ratio | -1,409.33% | -1,323.38% | -1,207.70% | -626.02% | -261.27% | -215.93% | -317.17% | -119.86% | -69.53% | -7.43% |
| Total Other Income/Expenses | 671.36K | -235.03K | 300.44K | 81.04K | -91.17K | -187.87K | -33.93K | -4.17K | -159.31K | -37.69K |
| Income Before Tax | -11.88M | -13.91M | -14.02M | -6.53M | -6.10M | -5.45M | -3.96M | -1.06M | -1.07M | -109.40K |
| Income Before Tax Ratio | -1,333.97% | -1,346.13% | -1,182.36% | -618.35% | -265.24% | -223.63% | -319.91% | -120.33% | -118.66% | -11.33% |
| Income Tax Expense | 0.00 | -211.26K | 1.00 | 100.77K | 508.00 | 465.85K | -18.62K | 0.00 | 0.00 | 0.00 |
| Net Income | -11.88M | -13.91M | -14.02M | -6.53M | -6.10M | -5.45M | -3.96M | -1.06M | -1.07M | -109.40K |
| Net Income Ratio | -1,333.97% | -1,346.13% | -1,182.36% | -618.35% | -265.24% | -223.63% | -319.91% | -120.33% | -118.66% | -11.33% |
| EPS | -0.06 | -0.07 | -0.07 | -0.04 | -0.06 | -0.08 | -0.14 | -0.99 | -1.49 | -0.17 |
| EPS Diluted | -0.06 | -0.07 | -0.07 | -0.04 | -0.06 | -0.08 | -0.14 | -0.99 | -1.49 | -0.17 |
| Weighted Avg Shares Out | 214.28M | 211.95M | 196.96M | 150.21M | 107.20M | 69.94M | 28.46M | 1.07M | 717.11K | 627.93K |
| Weighted Avg Shares Out (Dil) | 214.28M | 211.95M | 196.96M | 150.21M | 107.20M | 69.94M | 28.46M | 1.07M | 717.11K | 627.92K |
Polarean Raises $12.6 Million in Oversubscribed Financing Round to Accelerate XENOVIEW™ Commercialization and Strategic Growth Initiatives
DURHAM, NC and LONDON, June 20, 2024 (GLOBE NEWSWIRE) -- Polarean Imaging plc (AIM: POLX) (“Polarean” or the “Company”), a commercial-stage medical device leader in advanced Magnetic Resonance Imaging (MRI) of the lungs, announces the closing of a $12.6 million...
Polarean Imaging raises $10mln to commercialise XENOVIEW MRI
Polarean Imaging PLC (AIM:POLX, OTC:PLLWF) has raised $10 million of new equity with the proceeds earmarked to accelerate the commercialisation of XENOVIEW, the company's MRI technology. The placing, priced at 1p per share, was cornerstoned by major shareholder and industry...
Polarean Imaging raises $10mln to commercialise XENOVIEW MRI
Polarean Imaging PLC (AIM:POLX, OTC:PLLWF) has raised $10 million of new equity with the proceeds earmarked to accelerate the commercialisation of XENOVIEW, the company's MRI technology. The placing, priced at 1p per share, was cornerstoned by major shareholder and industry...
Polarean Imaging up by a quarter on new US order
Polarean Imaging shot up 23% on news on another order for its Xenon MRI lung imaging technology. University of Alabama at Birmingham (UAB) Hospital's order extends the company's technology to an additional major hospital for the first time, Polarean noted.
Polarean Imaging lands new hospital order for Xenon MRI System
Polarean Imaging PLC (AIM:POLX, OTC:PLLWF) announced its latest new order for a Xenon MRI System, from the University of Alabama at Birmingham (UAB) Hospital. The order from the hospital, a top-tier academic institution in the southeastern United States, extends the...
Polarean Imaging to showcase Xenon MRI at Respiratory Innovation Summit
Polarean Imaging PLC (AIM:POLX, OTC:PLLWF), a leader in advanced MRI technology, has been selected as a featured company and poster presenter at the upcoming American Thoracic Society's 2024 Respiratory Innovation Summit. A key gathering for those involved in pulmonary medicine, the...
Polarean Imaging receives order from Cincinnati Children's Hospital Medical Center
Polarean Imaging PLC (AIM:POLX, OTC:PLLWF), a leader in advanced magnetic resonance imaging (MRI) technology for lung function, has secured an order from Cincinnati Children's Hospital Medical Center for an upgraded polariser to replace an existing research unit. Cincinnati Children's, acclaimed...
Polarean Imaging lands US patent for cardiopulmonary blood flow imaging
Polarean Imaging PLC (AIM:POLX, OTC:PLLWF) has been granted a US patent for its pioneering use of Xenon magnetic resonance imaging (MRI) in cardiopulmonary blood flow imaging. This development marks a significant advancement in the diagnosis and monitoring of pulmonary vascular diseases (PVD), which...
Polarean Imaging lands US patent for cardiopulmonary blood flow imaging
Polarean Imaging PLC (AIM:POLX, OTC:PLLWF) has been granted a US patent for its pioneering use of Xenon magnetic resonance imaging (MRI) in cardiopulmonary blood flow imaging. This development marks a significant advancement in the diagnosis and monitoring of pulmonary vascular diseases (PVD), which...
Polarean Imaging outlines ambitious investment plans as it looks to commercialise XENOVIEW
Polarean Imaging PLC (AIM:POLX, OTC:PLLWF) has provided investors with detailed insight into how it intends to commercialise its groundbreaking XENOVIEW technology - a plan that would require at least $10m in additional investment. In the update, it said shareholders NUKEM Isotopes...
Source: https://incomestatements.info
Category: Stock Reports